Table 4.

Outcome of ibrutinib in first-line treatment of CLL with TP53 aberrations reported in real-world studies and in clinical trials.

N. of patients	Median age	Median follow-up (mos)	Discontinuation	Survival	ORR (%)	Type of study (reference)
747	71	26	36.6% at 24 mos.	82.6% at 24 mos	77.7	Present study
254	70	20.4	Median time to discontinuation 32.5 mos	Median 57.7 mos 88% at 12 mos	NR	RW [16]
111	68	13.8	33% overall	89% at 12 mos	82.3	RW [13]
100	71	24	32% at 24 mos.	92% at 24 months	79	RW [25]
89	65	49.8	54% overall	88% at 48 months	93	CT [9]
27	62	70	67% overall	79% at 6 years	96.2	CT [26]
34	63	78	50% overall	88% at 24 months	93.9	CT [8]

NR not reported, RW real world, CT clinical trial.